Literature DB >> 16428243

Non-adherence to endocrine therapy for breast cancer.

A H Partridge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16428243     DOI： 10.1093/annonc/mdj141

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  18 in total

1.  Is Chemoendocrine Treatment without Alternative?

Authors:  Richard Greil
Journal:  Breast Care (Basel)       Date:  2008-08-22       Impact factor: 2.860

Review 2.  Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes.

Authors:  Stewart J Levine; Sally E Wenzel
Journal:  Ann Intern Med       Date:  2010-02-16       Impact factor: 25.391

3.  Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.

Authors:  Renée Simon; Jean Latreille; Claire Matte; Pierre Desjardins; Eric Bergeron
Journal:  Can J Surg       Date:  2014-02       Impact factor: 2.089

4.  Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.

Authors:  Ilana Graetz; Caitlin N McKillop; Edward Stepanski; Gregory A Vidal; Janeane N Anderson; Lee S Schwartzberg
Journal:  J Cancer Surviv       Date:  2018-02-28       Impact factor: 4.442

Review 5.  Exogenous reproductive hormone use in breast cancer survivors and previvors.

Authors:  Ines Vaz-Luis; Ann H Partridge
Journal:  Nat Rev Clin Oncol       Date:  2018-01-23       Impact factor: 66.675

6.  Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).

Authors:  K J Ruddy; B N Pitcher; L E Archer; H J Cohen; E P Winer; C A Hudis; H B Muss; A H Partridge
Journal:  Ann Oncol       Date:  2012-07-05       Impact factor: 32.976

7.  Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.

Authors:  Matthias Kalder; Volker Ziller; Ioannis Kyvernitakis; Dana Knöll; Olaf Hars; Peyman Hadji
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-27       Impact factor: 4.553

8.  A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12).

Authors:  V H C Bramwell; K I Pritchard; D Tu; K Tonkin; H Vachhrajani; T A Vandenberg; J Robert; A Arnold; S E O'Reilly; B Graham; L Shepherd
Journal:  Ann Oncol       Date:  2009-07-23       Impact factor: 32.976

9.  Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.

Authors:  J M Rae; M J Sikora; N L Henry; L Li; S Kim; S Oesterreich; T C Skaar; A T Nguyen; Z Desta; A M Storniolo; D A Flockhart; D F Hayes; V Stearns
Journal:  Pharmacogenomics J       Date:  2009-05-05       Impact factor: 3.550

10.  Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research.

Authors:  Stephanie B Wheeler; Katherine E Reeder-Hayes; Lisa A Carey
Journal:  Oncologist       Date:  2013-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.